Janssen Search
Search results
Tina Soares
TINA SOARES GLOBAL HEAD SCIENTIFIC & CLINICAL OPERATIONS THE LUNG CANCER INITIATIVE AT J&J AND WORLD WITHOUT DISEASE ACCELERATOR As Global Head, Scientific & Clinical Operations for the Lung Cancer Initiative (LCI) at Johnson & Johnson (J ...
U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
Aug 10, 2023 United States Bispecific antibody targeting GPRC5D receptor showed an overall response rate of more than 70 percent with durable responses, including in patients previously treated with a bispecific antibody or CAR-T cell therapy HORSHAM, ...
Tackling the Stigma Around Plaque Psoriasis
Tackling the Stigma of Plaque Psoriasis Growing up with atopic dermatitis and severe plaque psoriasis, Howard Chang frequently encountered negativity because of his skin. In addition to managing the discomfort and painful symptoms of plaque psoriasis, ...
Peter Ronco
PETER RONCO HEAD GLOBAL DEVELOPMENT Peter Ronco is responsible for leading the Global Development organization in delivering the portfolio on time, within budget, and with robust quality while continuously improving to optimize efficiency and the patient ...
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
Sep 16, 2024 Spain TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence BARCELONA, September 16, 2024 – Johnson & Johnson (NYSE:JNJ) ...
Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Feb 06, 2023 United States There are currently no approved therapeutics for the treatment of HDFN which, in severe cases, can cause life-threatening anemia in the fetus SPRING HOUSE, PENNSYLVANIA, February 6, 2023 – The Janssen Pharmaceutical Companies ...
Johnson & Johnson Announces Expansion of IMBRUVICA® (ibrutinib) Label in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Approved Indications
Feb 26, 2024 United States IMBRUVICA ® is now the only Bruton’s tyrosine kinase inhibitor (BTKi) approved with an oral suspension formulation, providing additional flexibility for patients who may have difficulty swallowing tablets or capsules HORSHAM, PA ...
Lisa Shea
Lisa Shea Scientific Patient Engagement Leader Janssen Scientific Affairs Lisa Shea is the Scientific Patient Engagement Leader for Janssen Scientific Affairs. Lisa is responsible for bringing the patient perspective in-house and leveraging it to drive ...
TREMFYA® (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study
Oct 16, 2023 United States Key efficacy endpoints of the long-term extension GALAXI study included clinical remission, patient-reported outcome remission, and endoscopic response SPRING HOUSE, PENNSYLVANIA, October 16, 2023 – Janssen Pharmaceuticals, ...
New Phase 3 TREMFYA® (guselkumab) Results in Ulcerative Colitis Show a 77 Percent Overall Clinical Response Rate and Early Symptom Improvement
Oct 23, 2023 United States Data from the QUASAR induction study of a dults with moderate to severely active ulcerative colitis show clinically meaningful results at Weeks 12 or 24 Additional data show symptomatic response as early as one week after the ...